2
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Plasma cell
59
Lymphoid
1
Genitourinary
1
Conditions
Renal Insufficiency
1
Multiple Myeloma
1
Kidney Failure, Chronic
1
Interventions
Docetaxel
409
pembrolizumab
331
Prednisone
289
enzalutamide
283
Gemcitabine
274
Radiotherapy
270
Magnetic Resonance Spectroscopy
269
Nivolumab
252
Abiraterone Acetate
217
Cisplatin
212
Leuprolide
195
Radiosurgery
192
Sunitinib
188
Carboplatin
161
Androgen Antagonists
156
bicalutamide
152
Specimen Handling
149
Goserelin
149
Ipilimumab
131
Paclitaxel
126
acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide
122
apalutamide
117
Cyclophosphamide
117
Bevacizumab
116
Sorafenib
114
Everolimus
111
abiraterone
106
cabozantinib
104
atezolizumab
104
Biopsy
101
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
belantamab mafodotin
×
Genitourinary
×
Clear all
NCT04398745
2025-05-23
DREAMM12
GlaxoSmithKline
Phase 1
Active not recruiting
36 enrolled